Procainamide-induced agranulocytosis differs serologically and clinically from procainamide-induced lupus

Clinical Immunology and Immunopathology

Volumn 78, Issue 2, 1996, Pages 112-119

  Starkebaum, Gordon ^a,d   Kenyon, Christy M ^a   Simrell, Charles R ^a   Creamer, Joyce I ^b   Rubin, Robert L ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROCAINAMIDE;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ETIOLOGY; FOOD AND DRUG ADMINISTRATION; HUMAN; LUPUS VULGARIS; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0029959036     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1996.0020     Document Type: Article

References (66)

1. Azocar, J., Anti-myeloid-cell antibody in procainamide-induced agranulocytosis [letter]. Lancet 1, 1069-1070, 1984.
2. Antzis, E., Dunn, J., and Schelero, A., Pronesytyl (procaine amide) therapy in paroxysmal ventricular tachycardia. Am. Heart J. 43, 911-917, 1952.
3. Berger, B. E., and Hauser, D. J., Agranulocytosis due to new sustained-release procainamide. Am. Heart J. 105, 1035-1036, 1983.
4. Bluming, A. Z., Plotkin, D., Rosen, P., and Thiessen, A. R., Severe transient pancytopenia associated with procainamide ingestion. JAMA 236, 2520-2521, 1976.
5. Chelius, C. J., and Nunag, A. N., Procainamide reactions. Wis. Med. J. 74, 000-000, 1975.
6. Christensen, D. J., Palma, L. F., and Phelps, K., Agranulocytosis, thrombocytopenia, and procainamide [letter]. Ann. Intern. Med. 100, 000-000, 1984.
7. Clary, R. M., Beazley, W. D., and Henley, R. J., Fatal typhlitis secondary to procainamide-induced agranulocytosis. Va. Med. Mon. 111, 697-698, 1984.
8. Crook, J. E., Woosley, R. L., Leftwich, R. B., and Natelson, E. A., Agranulocytosis during combined procainamide and phenytoin therapy. South. Med. J. 72, 1599-1601, 1979.
9. Dross, V., Agranulocytosis due to procainamide hydrochloride. Md. St. Med. J. 23, 87-89, 1974.
10. Ellrodt, A. G., Murata, G. H., Riedinger, M. S., Stewart, M. E., Mochizuki, C., and Gray, R., Severe neutropenia associated with sustained-release procainamide. Ann. Intern. Med. 100, 197-201, 1984.
11. Fabregoule, M., and Messerschmitt, J., Agranulocytose au cours d'un traitement par l'amide procainique. Le Sang 25, 510-512, 1954.
12. Fleet, S., Agranulocytosis, procainamide, and phenytoin [letter]. Ann. Intern. Med. 100, 616-617, 1984.
13. Freed, J. S., and Reiner, M. A., Septic complications of procainamide-induced agranulocytosis: Report of two cases. Mt. Sinai J. Med. 55, 194-197, 1988.
14. Gunay, U., and Honig, G. R., Agranulocytosis in a 12-year-old girl treated with procainamide. Clin. Pediatr. 13, 728-730, 1974.
15. Hensen, A., Agranulocytosis caused by procainamide (Pronestyl) [Dut]. Ned. Tijdschr. Geneeshde. 118, 624-625, 1974.
16. Hickson, B., Davidson, R. J., and Walker, W., Agranulocytosis caused by procainamide. Scott. Med. J. 17, 165-168, 1972.
17. Hoffman, H. S., Severe neutropenia with procainamide therapy. Conn. Med. 54, 59-61, 1990.
18. Hoyt, R. E., Severe neutropenia due to sustained-release procainamide. South. Med. J. 80, 1196-1197, 1987.
19. Inouye, M., Millar, J., and Townsend, J., Agranulocytosis following maintenance dosage of Pronestyl. JAMA 147, 652-653, 1951.
20. Kimmel, D. P., Antignano, L. V., Barold, S. S., Boros, L., and Olson, J. P., Neutropenia associated with procainamide [letter]. NY State J. Med. 85, 000-000, 1985.
21. Konttinen, Y. P., and Tuominen, L., Reversible procainamide-induced agranulocytosis twice in one patient. Lancet 2, 000-000, 1971.
22. Kwan, V., Procainamide-induced leukopenia. J. Am. Geriatr. Soc. 17, 404-405, 1969.
23. Malters, P. B., and Salem, A. G., Agranulocytosis secondary to extended-release procainamide: A case report and review of the literature. A case of agranulocytosis caused by procainamide in a patient who had undergone open-heart surgery. S. D. J. Med. 40, 7-10, 1987.
24. Meyers, D. G., Gonzalez, E. R., Peters, L. L., Davis, R. B., Feagler, J. R., Egan, J. D., and Nair, C. K., Severe neutropenia associated with procainamide: Comparison of sustained release and conventional preparations. Am. Heart J. 109, 1393-1395, 1985.
25. Miller, H., Pollock, R., and Griffith, G., Fatal agranulocytosis resulting from a procaine derivative. J. Lab. Clin. Med. 38, 850-857, 1951.
26. Nagesh, K. G., Poulose, K. P., Tseng, T. H., and Schadchehr, A., Procainamide-induced agranulocytosis: Report of two cases and review. J. Ks. Med. Soc. 81, 18-24, 1980.
27. Nelson, J. C., Lutton, J. D., and Fass, A. E., Procainamide-induced agranulocytosis with reversible myeloid sensitivity. Am. J. Hematol. 17, 427-432, 1984.
28. Oster, Z. H., Agranulocytosis and lupus erythematosus phenom-enon after procaineamide. Israel J. Med. Sci. 2, 354-355, 1966.
29. Prince, R. A., Brown, B. T., and Jacknowitz, A. I., Agranulocytosis associated with procainamide therapy: Report of a case. Am. J. Hosp. Pharm. 34, 1362-1365, 1977.
30. Ream, C. R., and Barrera, R., Desensitization to procainamide. J. Med. Soc. N.J. 67, 107-110, 1970.
31. Reidy, T. J., and Upshaw, J. J., Procainamide-induced agranulocytosis. South. Med. J. 77, 1582-1584, 1984.
32. Riker, J., Baker, J., and Swanson, M., Bone marrow granulomas and neutropenia associated with procainamide: Report of a case. Arch. Intern. Med. 138, 1731-1732, 1978.
33. Rollag, A., Procainamide-induced agranulocytosis [Nor]. Tidsskr. Nor. Laegeforen. 102, 96-97, 1982.
34. Rothman, I. K., and Amorosi, E. L., Procainamide-induced agranulocytosis and thrombocytopenia. Arch. Intern. Med. 139, 246-247, 1979.
35. Shields, A. F., and Berenson, J. A., Procainamide-associated pancytopenia [see comments]. Am. J. Hematol. 27, 299-301, 1988.
36. Talmers, F., and Telmos, A., Procaine amide hydrochloride (Pronestyl)-induced agranulocytosis. Mich. Med. 64, 655-657, 1965.
37. Thompson, J., Robinson, C., and Segal, J., Procainamide agranulocytosis: A case report and review of the literature. Curr. Ther. Res. 44, 872-881, 1988.
38. Wang, R. I., and Schuller, G., Agranulocytosis following procainamide administration. Am. Heart J. 78, 282-284, 1969.
39. Fritzler, M., and Tan, E., Antibodies to histones in drug-induced and idiopathic lupus erythematosus. J. Clin. Invest. 62, 560-568, 1978.
40. Blomgren, S., Condemi, J., Bignall, M., and Vaughan, J., Antinuclear antibody induced by procainamide: A prospective study. N. Engl. J. Med. 281, 64-66, 1969.
41. Woosley, R., Drayer, D., Reidenberg, M., Nies, A., Carr, K., and Oates, J., Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N. Engl. J. Med. 298, 1157-1159, 1978.
42. Cush, J. J., and Goldings, E. A., Drug-induced lupus: Clinical spectrum and pathogenesis. Am. J. Med. Sci. 290, 36-45, 1985.
43. Henningsen, N., Cederberg, A., Hanson, A., and Johansson, B., Effects of long-term treatment with procaine amide: A prospective study with special regard to ANF and SLE in fast and slow acetylators. Acta Med. Scand. 198, 475-482, 1975.
44. Kosowsky, B., Taylor, J., Lown, B., and Ritchie, R., Long-term use of procaine amide following acute myocardial infarction. Circulation 47, 1204-1210, 1973.
45. Dubois, E., Procainamide induction of a systemic lupus erythematosus-like syndrome: Presentation of six cases, review of the literature, and analysis and followup of reported cases. Medicine 48, 217-228, 1969.
46. Weinstein, A., Drug-induced systemic lupus erythematosus. Prog. Clin. Immunol. 4, 1-21, 1980.
47. Hess, E., and Mongey, A.-B., Drug-related lupus: The same as or different from idiopathic disease? In "Systemic Lupus Erythematosus" (R. G. Lahita, Ed.), pp. 893-904, Churchill Livingstone, New York, 1992.
48. Totoritis, M. C., Tan, E. M., McNally, E. M., and Rubin, R. L., Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. N. Engl. J. Med. 318, 1431-1436, 1988.
49. Burlingame, R. W., and Rubin, R. L., Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J. Clin. Invest. 88, 680-690, 1991.
50. Blomgren, S., Condemi, J., and Vaughan, J., Procainamide-induced lupus erythematosus: Clinical and laboratory observations. Am. J. Med. 52, 338-348, 1972.
51. Rubin, R., Burlingame, R., Arnott, J., Totoritis, M., McNally, E., and Johnson, A., IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide-induced lupus. J. Immunol. 154, 2483-2493, 1995.
52. Fleit, H., Wright, S., and Unkless, J., Human neutrophil Frγ receptor distribution and structure. Proc. Natl. Acad. Sci. USA 79, 3275-3279, 1982.
53. Burlingame, R. W., and Rubin, R. L., Subnucleosome structures as substrates in enzyme-linked immunosorbent assays. J. Immunol. Methods 134, 187-199, 1990.
54. Kleinman, S., Nelson, R., Smith, L., and Goldfinger, D., Positive direct antiglobulin tests and immune hemolytic anemia in patients receiving procainamide. N. Engl. J. Med. 311, 809-812, 1984.
55. Becker, M., Klajman, A., Moalemm, T., Yaretzky, A., and BenEfraim, S., Circulating immune complexes in sera from patients receiving procainamide. Clin. Immunol. Immunopathol. 12, 220-227, 1979.
56. Klebanoff, S., and Hamon, C., Role of myeloperoxidase-mediated antimicrobial systems in intact leukocytes. J. Reticuloendothel. Soc. 12, 170-196, 1972.
57. Johnston, R. J., and Lehmeyer, J., Elaboration of toxic oxygen by-products by neutrophils in a model of immune complex disease. J. Clin. Invest. 57, 836-841, 1976.
58. Starkebaum, G., Stevens, D., Henry, C., and Gavin, S., Stimulation of human neutrophil chemiluminescence by soluble immune complexes and antibodies to neutrophils. J. Lab. Clin. Med. 98, 280-292, 1981.
59. Rubin, R. L., and Curnutte, J. T., Metabolism of procainamide to the cytotoxic hydroxylamine by neutrophils activated in vitro. J. Clin. Invest. 83, 1336-1343, 1989.
60. Rubin, R. L., Uetrecht, J. P., and Jones, J. E., Cytotoxicity of oxidative metabolites of procainamide. J. Pharmacol. Exp. Ther. 242, 833-841, 1987.
61. Adams, L. E., Sanders, C. E., Budinsky, R. A., Donovan-Brand, R., Roberts, S. M., and Hess, E. V., Immunomodulatory effects of procainamide metabolites: Their implications in drug-related lupus. J. Lab. Clin. Med. 113, 482-492, 1989.
62. Uetrecht, J., Drug metabolism by leukocytes and its role in druginduced lupus and other idiosyncratic drug reactions. Crit. Rev. Toxicol. 20, 213-235, 1990.
63. Waldhauser, L., and Uetrecht, J., Oxidation of propylthiouracil to reactive metabolites by activated neutrophils: Implications for agranulocytosis. Drug Metab. Disp. 19, 345-359, 1991.
64. Jiang, X., Khursigara, G., and Rubin, R. L., Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 266, 810-813, 1994.
65. Hofstra, A., Matassa, L., and Uetrecht, J., Metabolism of hydralazine by activated leukocytes: Implications for hydralazine-induced lupus. J. Rheumatol. 18, 1673-1680, 1991.
66. Aucoin, D. P., Rubin, R. L., Peterson, M. E., Reidenberg, M. M., Drayer, D. E., Hurvitz, A. I., and Lahita, R. G., Dose-dependent induction of anti-native DNA antibodies in cats by propylthiouracil. Arthritis Rheum. 31, 688-692, 1988.